SCHEMBL376646

SCHEMBL376646

CC(C)c1oc(-c2ccccc2Cl)nc1C/C=C/c1ccc(O)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 3/20 0.42
PPARA Q07869 3/20 0.42
PPARD Q03181 1/20 0.42
SMN1; SMN2 Q16637 4/20 0.37
ALDH1A1 P00352 3/20 0.37
TP53 P04637 3/20 0.37
LMNA P02545 2/20 0.37
POLB P06746 2/20 0.37
PTBP1 P26599 1/20 0.37
KDM4E B2RXH2 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MAPT P10636 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
PLA2G1B P04054 1/20 0.36
ATG4B Q9Y4P1 1/20 0.36
MEN1 O00255 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL376647 1.00 PPARG (0.42) PPARGPPARAPPARDSMN1; SMN2ALDH1A1
SCHEMBL377050 0.83 PPARA (0.62) PPARGPPARAPPARD
SCHEMBL377051 0.83 PPARA (0.62) PPARGPPARAPPARD
SCHEMBL381707 0.80 PPARA (0.51) PPARGPPARAPPARDCYP1A2CYP3A4
SCHEMBL381706 0.80 PPARA (0.51) PPARGPPARAPPARDCYP1A2CYP3A4
SCHEMBL2466991 0.77 PPARG (0.44) PPARGPPARAPPARDSMN1; SMN2ALDH1A1
SCHEMBL5845568 0.77 PPARG (0.51) PPARGPPARAPPARDSMN1; SMN2ALDH1A1
SCHEMBL5845282 0.77 KDM4E (0.50) PPARGPPARAPPARDSMN1; SMN2ALDH1A1
SCHEMBL377231 0.76 PPARG (0.46) PPARGPPARAPPARDSMN1; SMN2ALDH1A1
SCHEMBL376642 0.76 PPARG (0.45) PPARGPPARAPPARDSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1310494-B1 PPAR (delta) ACTIVATORS NIPPON CHEMIPHAR CO (JP) 2012-01-25 EP disclosed
US-6787552-B2 HYPERGLYCEMIA, HYPERLIPIDEMIA, OBESITY, SYNDROME X; OXAZOLE OR THIAZOLE OR IMIDAZOLE DERIVATIVES NIPPON CHEMIPHAR CO., LTD. (JP) 2004-09-07 US disclosed
US-20040097739-A1 Ppar delta activators NIPPON CHEMIPHAR CO., LTD. (JP) 2004-05-20 US disclosed
EP-1310494-A1 PPAR (delta) ACTIVATORS NIPPON CHEMIPHAR CO., LTD. (JP) 2003-05-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097739-A1 Ppar delta activators PPARD, PPARG, PPARA PPARG 2/4885PPARA 3/4885PPARD 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.